Results of treatment of malignant germ cell tumors in 93 children: A report from the Childrens Cancer Study Group

A. R. Ablin, M. D. Krailo, N. K.C. Ramsay, Marcio Malogolowkin, H. Isaacs, R. B. Raney, J. Adkins, D. M. Hays, D. R. Benjamin, J. L. Grosfeld, S. L. Leikin, M. Deutsch, G. D. Hammond

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

We report treatment results in 93 children entered on study from 1978 to 1984 with malignant germ cell tumors (MGCTs), excluding dysgerminoma and tumors of the testis or brain. The estimated 4-year survival and event-free survival (EFS) for all 93 patients were 54% and 49%, respectively. For 30 children with ovarian tumors, the estimated 4-year survival was 67% and EFS was 63%. For 63 children with nongonadal tumors, survival and EFS were 48% and 42%, respectively. The comparison of EFS between ovarian and nongonadal tumors was significant at P = .03. The treatment plan included a second-look surgical procedure after 18 weeks of chemotherapy. Over half of 36 patients evaluated as having a residual mass present immediately before second-look surgery had no malignant tumor after review of surgical specimens. Age greater than 11 years at diagnosis, incomplete removal of tumor at first surgery, and more than one structure or organ involved at diagnosis increased the risk for adverse event. The histologic subtype of the primary tumor was not related to outcome. Diagnosis was verified by independent pathologic review, and treatment was uniform. Seventeen percent of all registered patients (21 of 127) were excluded because of ineligible pathologic diagnoses; sixty percent (13 of 21) were immature teratomas.

Original languageEnglish (US)
Pages (from-to)1782-1792
Number of pages11
JournalJournal of Clinical Oncology
Volume9
Issue number10
DOIs
StatePublished - Jan 1 1991
Externally publishedYes

Fingerprint

Germ Cell and Embryonal Neoplasms
Disease-Free Survival
Neoplasms
Therapeutics
Survival
Second-Look Surgery
Dysgerminoma
Teratoma
Testis
Drug Therapy
Brain

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Results of treatment of malignant germ cell tumors in 93 children : A report from the Childrens Cancer Study Group. / Ablin, A. R.; Krailo, M. D.; Ramsay, N. K.C.; Malogolowkin, Marcio; Isaacs, H.; Raney, R. B.; Adkins, J.; Hays, D. M.; Benjamin, D. R.; Grosfeld, J. L.; Leikin, S. L.; Deutsch, M.; Hammond, G. D.

In: Journal of Clinical Oncology, Vol. 9, No. 10, 01.01.1991, p. 1782-1792.

Research output: Contribution to journalArticle

Ablin, AR, Krailo, MD, Ramsay, NKC, Malogolowkin, M, Isaacs, H, Raney, RB, Adkins, J, Hays, DM, Benjamin, DR, Grosfeld, JL, Leikin, SL, Deutsch, M & Hammond, GD 1991, 'Results of treatment of malignant germ cell tumors in 93 children: A report from the Childrens Cancer Study Group', Journal of Clinical Oncology, vol. 9, no. 10, pp. 1782-1792. https://doi.org/10.1200/JCO.1991.9.10.1782
Ablin, A. R. ; Krailo, M. D. ; Ramsay, N. K.C. ; Malogolowkin, Marcio ; Isaacs, H. ; Raney, R. B. ; Adkins, J. ; Hays, D. M. ; Benjamin, D. R. ; Grosfeld, J. L. ; Leikin, S. L. ; Deutsch, M. ; Hammond, G. D. / Results of treatment of malignant germ cell tumors in 93 children : A report from the Childrens Cancer Study Group. In: Journal of Clinical Oncology. 1991 ; Vol. 9, No. 10. pp. 1782-1792.
@article{53594f331a854c118c712379d32a0a48,
title = "Results of treatment of malignant germ cell tumors in 93 children: A report from the Childrens Cancer Study Group",
abstract = "We report treatment results in 93 children entered on study from 1978 to 1984 with malignant germ cell tumors (MGCTs), excluding dysgerminoma and tumors of the testis or brain. The estimated 4-year survival and event-free survival (EFS) for all 93 patients were 54{\%} and 49{\%}, respectively. For 30 children with ovarian tumors, the estimated 4-year survival was 67{\%} and EFS was 63{\%}. For 63 children with nongonadal tumors, survival and EFS were 48{\%} and 42{\%}, respectively. The comparison of EFS between ovarian and nongonadal tumors was significant at P = .03. The treatment plan included a second-look surgical procedure after 18 weeks of chemotherapy. Over half of 36 patients evaluated as having a residual mass present immediately before second-look surgery had no malignant tumor after review of surgical specimens. Age greater than 11 years at diagnosis, incomplete removal of tumor at first surgery, and more than one structure or organ involved at diagnosis increased the risk for adverse event. The histologic subtype of the primary tumor was not related to outcome. Diagnosis was verified by independent pathologic review, and treatment was uniform. Seventeen percent of all registered patients (21 of 127) were excluded because of ineligible pathologic diagnoses; sixty percent (13 of 21) were immature teratomas.",
author = "Ablin, {A. R.} and Krailo, {M. D.} and Ramsay, {N. K.C.} and Marcio Malogolowkin and H. Isaacs and Raney, {R. B.} and J. Adkins and Hays, {D. M.} and Benjamin, {D. R.} and Grosfeld, {J. L.} and Leikin, {S. L.} and M. Deutsch and Hammond, {G. D.}",
year = "1991",
month = "1",
day = "1",
doi = "10.1200/JCO.1991.9.10.1782",
language = "English (US)",
volume = "9",
pages = "1782--1792",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - Results of treatment of malignant germ cell tumors in 93 children

T2 - A report from the Childrens Cancer Study Group

AU - Ablin, A. R.

AU - Krailo, M. D.

AU - Ramsay, N. K.C.

AU - Malogolowkin, Marcio

AU - Isaacs, H.

AU - Raney, R. B.

AU - Adkins, J.

AU - Hays, D. M.

AU - Benjamin, D. R.

AU - Grosfeld, J. L.

AU - Leikin, S. L.

AU - Deutsch, M.

AU - Hammond, G. D.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - We report treatment results in 93 children entered on study from 1978 to 1984 with malignant germ cell tumors (MGCTs), excluding dysgerminoma and tumors of the testis or brain. The estimated 4-year survival and event-free survival (EFS) for all 93 patients were 54% and 49%, respectively. For 30 children with ovarian tumors, the estimated 4-year survival was 67% and EFS was 63%. For 63 children with nongonadal tumors, survival and EFS were 48% and 42%, respectively. The comparison of EFS between ovarian and nongonadal tumors was significant at P = .03. The treatment plan included a second-look surgical procedure after 18 weeks of chemotherapy. Over half of 36 patients evaluated as having a residual mass present immediately before second-look surgery had no malignant tumor after review of surgical specimens. Age greater than 11 years at diagnosis, incomplete removal of tumor at first surgery, and more than one structure or organ involved at diagnosis increased the risk for adverse event. The histologic subtype of the primary tumor was not related to outcome. Diagnosis was verified by independent pathologic review, and treatment was uniform. Seventeen percent of all registered patients (21 of 127) were excluded because of ineligible pathologic diagnoses; sixty percent (13 of 21) were immature teratomas.

AB - We report treatment results in 93 children entered on study from 1978 to 1984 with malignant germ cell tumors (MGCTs), excluding dysgerminoma and tumors of the testis or brain. The estimated 4-year survival and event-free survival (EFS) for all 93 patients were 54% and 49%, respectively. For 30 children with ovarian tumors, the estimated 4-year survival was 67% and EFS was 63%. For 63 children with nongonadal tumors, survival and EFS were 48% and 42%, respectively. The comparison of EFS between ovarian and nongonadal tumors was significant at P = .03. The treatment plan included a second-look surgical procedure after 18 weeks of chemotherapy. Over half of 36 patients evaluated as having a residual mass present immediately before second-look surgery had no malignant tumor after review of surgical specimens. Age greater than 11 years at diagnosis, incomplete removal of tumor at first surgery, and more than one structure or organ involved at diagnosis increased the risk for adverse event. The histologic subtype of the primary tumor was not related to outcome. Diagnosis was verified by independent pathologic review, and treatment was uniform. Seventeen percent of all registered patients (21 of 127) were excluded because of ineligible pathologic diagnoses; sixty percent (13 of 21) were immature teratomas.

UR - http://www.scopus.com/inward/record.url?scp=0026095874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026095874&partnerID=8YFLogxK

U2 - 10.1200/JCO.1991.9.10.1782

DO - 10.1200/JCO.1991.9.10.1782

M3 - Article

C2 - 1717667

AN - SCOPUS:0026095874

VL - 9

SP - 1782

EP - 1792

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -